Aliases & Classifications for Prostate Disease

Summaries for Prostate Disease

MedlinePlus : 43 The prostate is a gland in men. It helps make semen, the fluid that contains sperm. The prostate surrounds the tube that carries urine away from the bladder and out of the body. A young man's prostate is about the size of a walnut. It slowly grows larger with age. If it gets too large, it can cause problems. This is very common after age 50. The older men get, the more likely they are to have prostate trouble. Some common problems are Prostatitis - inflammation, usually caused by bacteria Enlarged prostate (BPH), or benign prostatic hyperplasia - a common problem in older men which may cause dribbling after urination or a need to go often, especially at night Prostate cancer - a common cancer that responds best to treatment when detected early NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Prostate Disease, also known as prostatic diseases, is related to prostate cancer and prostatitis, and has symptoms including angina pectoris, tremor and prostatism. An important gene associated with Prostate Disease is PCA3 (Prostate Cancer Associated 3
Diagnostic marker
Dysfunction Pattern: Expression [differentially expressed]). The drugs Lenograstim and Menthol have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and testes.

Wikipedia : 76 The prostate (from Ancient Greek προστάτης, prostates, literally \"one who stands before\",... more...

Related Diseases for Prostate Disease

Diseases related to Prostate Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 21.3 CBR3-AS1 CDKN2B-AS1 CTBP1-AS GAS5 H19 IGF2-AS
2 prostatitis 11.0
3 gastric cardia adenocarcinoma 10.2 H19 MEG3
4 astrocytoma 10.2 H19 PCA3 PRNCR1
5 coronary artery anomaly 10.1 CDKN2B-AS1 GAS5 H19 IGF2-AS
6 vulva squamous cell carcinoma 9.8 MALAT1 MEG3
7 aging 9.8
8 wilms tumor 1 9.8 H19 IGF2-AS MEG3
9 pituitary adenoma 9.7 H19 MALAT1 MEG3
10 bladder urothelial carcinoma 9.6 GAS5 MALAT1 MEG3
11 oral squamous cell carcinoma 9.6 H19 MALAT1 MEG3
12 insulin-like growth factor i 9.6
13 prostatic hyperplasia, benign 9.6
14 thyroid cancer 9.6 CDKN2B-AS1 GAS5 H19 MALAT1
15 ovarian epithelial cancer 9.5 H19 MALAT1 MEG3 PCA3
16 liver cirrhosis 9.5 GAS5 MALAT1 MEG3
17 kidney cancer 9.5 GAS5 H19 MALAT1 MEG3
18 breast cancer 9.5
19 myocardial infarction 9.5
20 male infertility 9.5
21 prostatic hypertrophy 9.5
22 rectal disease 9.5
23 papilledema 9.5
24 acromegaly 9.5
25 ischemia 9.5
26 infertility 9.5
27 endotheliitis 9.5
28 thyroid cancer, nonmedullary, 1 9.4 GAS5 H19 MALAT1 MEG3
29 squamous cell carcinoma 9.4 CBR3-AS1 CDKN2B-AS1 H19 MALAT1 PCAT1
30 osteoarthritis 9.4 GAS5 H19 MEG3 PCGEM1
31 gallbladder cancer 9.4 CDKN2B-AS1 H19 MALAT1 MEG3
32 lung cancer susceptibility 3 9.4 GAS5 H19 MALAT1 MEG3
33 myeloma, multiple 9.1 GAS5 H19 MALAT1 MEG3 PCAT1
34 osteogenic sarcoma 9.1 CDKN2B-AS1 H19 MALAT1 MEG3 PCAT1
35 nasopharyngeal carcinoma 9.1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
36 melanoma 9.0 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
37 endometrial cancer 8.9 GAS5 H19 MEG3 PTENP1
38 neuroblastoma 8.9 GAS5 H19 MALAT1 MEG3
39 pancreatic cancer 8.9 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
40 renal cell carcinoma, nonpapillary 8.8 GAS5 H19 LINC00963 MALAT1 PTENP1
41 glioma 8.8 CBR3-AS1 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
42 esophageal cancer 8.8 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
43 ovarian cancer 8.7 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3
44 adamantinoma of long bones 8.4 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
45 cervical cancer 8.4 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
46 bladder cancer 8.4 CDKN2B-AS1 GAS5 H19 MALAT1 MEG3 PCAT1
47 malignant glioma 8.2 CDKN2B-AS1 GAS5 H19 LINC00963 MALAT1 MEG3
48 glioblastoma 8.2 GAS5 H19 LINC00963 MALAT1 MEG3 PCAT1
49 lung cancer 8.0 CDKN2B-AS1 GAS5 H19 IGF2-AS MALAT1 MEG3
50 hepatocellular carcinoma 7.8 CBR3-AS1 CDKN2B-AS1 GAS5 H19 IGF2-AS MALAT1

Comorbidity relations with Prostate Disease via Phenotypic Disease Network (PDN):


Prostate Cancer Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Prostate Disease:



Diseases related to Prostate Disease

Symptoms & Phenotypes for Prostate Disease

UMLS symptoms related to Prostate Disease:


angina pectoris, tremor, prostatism, equilibration disorder

Drugs & Therapeutics for Prostate Disease

Drugs for Prostate Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 824)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
2
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
4
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
5
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 2180-92-9, 38396-39-3 2474
6
Doxazosin Approved Phase 4,Phase 3,Phase 2,Not Applicable 74191-85-8 3157
7
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 81403-80-7 2092
8
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13311-84-7 3397
9
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98319-26-7 57363
10
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
12
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65807-02-5 47725 5311128
13
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
14
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106133-20-4 129211
15
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 152945 6918296
16
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 75614-87-8, 51-45-6 774
17
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
18
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
19
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
20
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
21
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-22-0 6013
22
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53714-56-0 3911 657181
23
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90357-06-5 56069 2375
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
26
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
27
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
28
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
29
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
30
Povidone Approved Phase 4 9003-39-8
31
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
32
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
33
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 615258-40-7
34
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
35
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
36
Dihydrotachysterol Approved Phase 4,Phase 2 67-96-9 5281010 5311071
37
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
38
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
39
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
40
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
41
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
42
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
43
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
44
Midazolam Approved, Illicit Phase 4,Phase 1,Not Applicable 59467-70-8 4192
45
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
46
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
47
Prazosin Approved Phase 4,Not Applicable 19216-56-9 4893
48
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
49
Terazosin Approved Phase 4,Not Applicable 63590-64-7 5401
50
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 147-24-0, 58-73-1 3100

Interventional clinical trials:

(show top 50) (show all 3953)
# Name Status NCT ID Phase Drugs
1 A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy Unknown status NCT02245334 Phase 4 Povidone-Iodine
2 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
3 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Unknown status NCT02749604 Phase 4
4 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
5 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
6 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
7 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
8 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
9 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
10 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
11 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
12 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
13 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
14 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
15 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
16 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
17 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
18 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
19 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
20 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
21 Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study Completed NCT00575913 Phase 4 Alfuzosin
22 Treatment of Chronic Bacterial Prostatitis Completed NCT02130713 Phase 4 Third generation fluoroquinolone
23 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
24 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
25 A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy Completed NCT02423759 Phase 4 ciprofloxacin;ciprofloxacin and gentamycine;culture based chemoprophylaxis
26 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
27 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
28 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
29 KTP Green Light Prostatectomy Compared With Open Prostatectomy Completed NCT02072499 Phase 4
30 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
31 Prospective Sexual Function Study for BPH Subjects Completed NCT01777269 Phase 4 Dutasteride plus tamsulosin;Placebo
32 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
33 Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration Completed NCT01675895 Phase 4 Levobupivacaine lidocaine spinal anesthesia;levobupivacaine Spinal anesthesia
34 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
35 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
36 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
37 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
38 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
39 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
40 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
41 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
42 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
43 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
44 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
45 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
46 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
47 Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Completed NCT00199550 Phase 4
48 Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels Completed NCT00062790 Phase 4 Dutasteride
49 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin
50 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4 Dutasteride

Search NIH Clinical Center for Prostate Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: prostatic diseases

Genetic Tests for Prostate Disease

Anatomical Context for Prostate Disease

MalaCards organs/tissues related to Prostate Disease:

41
Prostate, Bone, Testes, Lymph Node, Lung, T Cells, Kidney

Publications for Prostate Disease

Articles related to Prostate Disease:

(show top 50) (show all 179)
# Title Authors Year
1
Setting up a service for men with benign prostate disease. ( 29561636 )
2018
2
Canine Prostate Disease. ( 29933768 )
2018
3
Association between male pattern baldness and prostate disease: A meta-analysis. ( 29054497 )
2018
4
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives. ( 29335762 )
2018
5
Re: Evolution of Primary Care Referrals to Urology. Impact of a Protocol on Prostate Disease and Continuing Education. ( 29144897 )
2017
6
Dynamic instrumented palpation - a new method for soft tissue quality assessment: application to prostate disease diagnosis. ( 28965477 )
2017
7
Over-Expression of Activin-I^C Is Associated with Murine and Human Prostate Disease. ( 28116672 )
2017
8
Positive Response to Thermobalancing Therapy Enabled by Therapeutic Device in Men with Non-Malignant Prostate Diseases: BPH and Chronic Prostatitis. ( 28933398 )
2016
9
Erratum: Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27436144 )
2016
10
Comparative study of serum zinc concentrations in benign and malignant prostate disease: A Systematic Review and Meta-Analysis. ( 27170414 )
2016
11
Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 27845125 )
2016
12
Prostatectomy for benign prostate disease: open, laparoscopic and robotic techniques. ( 26497345 )
2015
13
The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients. ( 25665470 )
2015
14
Initial Evaluation of the Safety of Nanoshell-Directed Photothermal Therapy in the Treatment of Prostate Disease. ( 26296672 )
2015
15
Testosterone Replacement Therapy on the Natural History of Prostate Disease. ( 26077355 )
2015
16
Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level. ( 29264129 )
2015
17
Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. ( 25323935 )
2015
18
Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. ( 26171936 )
2015
19
MALDI MS profiling of post-DRE urine samples highlights the potential of I^-microseminoprotein as a marker for prostatic diseases. ( 24115268 )
2014
20
Lycopene for the prevention and treatment of prostate disease. ( 24531784 )
2014
21
Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education. ( 25554605 )
2014
22
Serum amyloid A, phospholipase Aa88-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases. ( 24061501 )
2013
23
Androgens and prostate disease. ( 24407178 )
2013
24
Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications. ( 23690774 )
2013
25
Effect of microbubble-enhanced ultrasound on prostate permeability: a potential therapeutic method for prostate disease. ( 23414693 )
2013
26
Current status of 5I+-reductase inhibitors in prostate disease management. ( 23614056 )
2013
27
Seminal plasma glycoproteins in male infertility and prostate diseases: is there a chance for glyco-biomarkers? ( 23061682 )
2013
28
Treatment for prostate disease should be uniform across the UK. ( 27794764 )
2012
29
Patient reported incontinence after radical prostatectomy is more common than expected and not associated with the nerve sparing technique: results from the Center for Prostate Disease Research (CPDR) database. ( 21826727 )
2012
30
Can a Gleason 6 or Less Microfocus of Prostate Cancer in One Biopsy and Prostate-Specific Antigen Level <10a88ng/mL Be Defined as the Archetype of Low-Risk Prostate Disease? ( 22848218 )
2012
31
Prostate disease risk factors among a New Zealand cohort. ( 23363810 )
2012
32
Botulinum toxin A in prostate disease: a venom from bench to bed-side. ( 22409179 )
2012
33
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-I+ and GPER signalling. ( 22233684 )
2012
34
Risk of prostate cancer associated with benign prostate disease: a primary care case-control study. ( 22054323 )
2011
35
The value of contrast-enhanced transrectal ultrasound in predicting the nature of prostate diseases and the Gleason score of prostate cancer by a subjective blood flow grading scale. ( 21832814 )
2011
36
Detecting gene-gene interactions in prostate disease in African American men. ( 21992608 )
2011
37
Cholesterol and benign prostate disease. ( 21862201 )
2011
38
Correlation between age and Chromogranin A determination in prostate diseases. ( 22674297 )
2011
39
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. ( 21091976 )
2011
40
Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. ( 21079217 )
2010
41
N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. ( 19956848 )
2010
42
ACR appropriateness criteria on obstructive voiding symptoms secondary to prostate disease. ( 20362939 )
2010
43
The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. ( 20535861 )
2010
44
Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. ( 20647404 )
2010
45
A new vision for the study of benign prostate disease: the NIDDK Prostate Research Strategic Plan. ( 19150562 )
2009
46
Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. ( 19021204 )
2009
47
Clinical guidelines: should 5 alpha-reductase inhibitors be used for prostate disease? ( 19578352 )
2009
48
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. ( 19267353 )
2009
49
Evaluation of ischemia-modified albumin in myocardial infarction and prostatic diseases. ( 19375269 )
2009
50
The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research. ( 19720304 )
2009

Variations for Prostate Disease

Expression for Prostate Disease

Search GEO for disease gene expression data for Prostate Disease.

Pathways for Prostate Disease

GO Terms for Prostate Disease

Sources for Prostate Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....